OSE — Ose Immunotherapeutics SA Share News
0.000.00%
Last trade - 00:00- €44.94m
- €57.66m
- €2.69m
Brief: OSE Immunotherapeutics And Boehringer Ingelheim Present Positive Phase 1 Results With SIRPα Inhibitor BI 765063
Brief: OSE Immunotherapeutics: Additional Financing For Its COVID Vaccine Candidate
Brief: Ose Immunotherapeutics, Veloxis Sign Global License Agreement On FR104
French and Benelux stocks-Factors to watch
Brief: Ose Immunotherapeutics' COVID-19 Vaccine Gets Approval For Phase 1 Clinical Trial
Brief: OSE Immunotherapeutics End-December Net Loss Widens To 16.6 Million Euros
Brief: Ose Immunotherapeutics Announces Granting Of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011
Brief: OSE Immunotherapeutics Enters Loan Agreement Of Up To Eur 25 Mln With European Investment Bank
Brief: OSE Immunotherapeutics Expands Collaboration With MAbSilico On AI
Brief: OSE Immunotherapeutics Receives EUR 1.3 Mln Milestone Payment From Bpifrance
Brief: Ose ImmunotherapeuticS Enrols First Patient In Phase 2 Trial Testing Of OSE-127/S95011
Brief: Ose Immunotherapeutics Gets EUR 5.2 Mln In Public Funding For Development Of Its 2nd Generation Covid-19 Vaccine
Brief: OSE Immunotherapeutics, Nantes University Hospital Initiate Phase 1/2 Clinical Trial To Evaluate CD28 Antagonist FR104
Brief: Ose Immunotherapeutics: Successful Capital Increase Of 18.6 Million Euros
Brief: Ose Immunotherapeutics Provides Covid-19 Vaccine Update On Covepit
Brief: OSE Immunotherapeutics: OSE-230 Triggers Resolution Of Chronic Inflammation
Brief: OSE Immunotherapeutics Receives European Patent Notice Of Allowance For First-In-Class CD28-Antagonist Immunotherapy FR104
Brief: Ose Immunotherapeutics: European Patent Notice Of Allowance For FR104
Brief: Ose Immunotherapeutics: European Patent Notice Of Allowance For FR104